diabetic nephropathy

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.

Named PromarkerD, the test is intended to predict risk of developing kidney disease in diabetics and diagnose patients with diabetic kidney disease.

Proteomics firm Proteomics International said this week that it has received a A$1 million (US$ 1 million) grant from Commercialisation Australia – an initiative of the Australian government – to develop its protein biomarkers for diabetic nephropathy into a companion diagnostic.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – EMD Millipore and Proteomic International have signed a collaborative agreement to validate biomarkers related to diabetic nephropathy, the firms said today.

The company presented a panel of 13 biomarkers for the disease at last month's Human Proteome Organization annual meeting and is looking for partners and funding to develop it as a commercial diagnostic.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.